EV25 Reduces Influenza Viral Loads
This is a news story, published by ScienceDaily, that relates primarily to Nielsen news.
Nielsen news
For more Nielsen news, you can click here:
more Nielsen newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsScienceDaily news
For more news from ScienceDaily, you can click here:
more news from ScienceDailyAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Eradivir drug compounds. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest influenza virus infection news, influenza virus news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
antiviral therapeuticScienceDaily
•Eradivir's EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies
81% Informative
Eradivir's EV25 therapeutic reduces advanced-stage influenza viral loads faster, more thoroughly in preclinical studies than current therapies.
A single intranasal dose of EV25 acts faster than the current standard of care, eliminating the detectable virus within 24 hours .
EV25 also has a window of efficacy of 96 hours postinfection, which is broader than current standard care.
Both EV25 and the RSV therapeutic are built on the BAiT platform, or Bispecific Antigenic immunoTherapy, developed at Purdue .
"EV25 is a game changer in how effective it is compared to existing therapeutics in preclinical models," Nielsen said.
VR Score
91
Informative language
97
Neutral language
73
Article tone
formal
Language
English
Language complexity
74
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links